| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1059: Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma |
|
Medicine details |
|
| Medicine name | brentuximab vedotin (Adcetris®) |
| Formulation | 50 mg powder for concentrate for solution for infusion |
| Reference number | 2074 |
| Indication | Adult patients with previously untreated CD30+ Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD) |
| Company | Takeda UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 11/06/2019 |
| NICE guidance | TA1059: Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma |